NanoViricides Inc., a clinical stage company specializing in broad-spectrum antivirals, has announced promising results from their recent animal study involving NV-387, a drug candidate aimed at treating Measles. The study utilized humanized mice to simulate Measles infection, as the virus does not naturally infect mice. NV-387 demonstrated a significant increase in survival rates, extending the average lifespan of infected animals from 7.4 days to 17 days, without any observed toxicity. The drug, designed to mimic cellular features essential for viral binding, showed a dose-dependent improvement in survival. These results indicate NV-387's potential as the first drug to effectively treat Measles, as global cases continue to rise.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.